pre-FLAMENCT06422546
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary endpoint(s) modified.
See at-risk trials from Beijing Cancer Prevention & Treatment Society
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Start date pushed from Dec 28, 2021 to Jan 13, 2022
- Notable: the plan changed
Endpoints
Primary
To describe the characteristics of EGFR mutation changes at baseline and after 3 weeks of osimertinib treatment
Timeframe: baseline and after three weeks of osimertinib treatment
Secondary (1)
To evaluate the changes in EGFR mutations at baseline and after 3weeks treatment,and their correlation with the therapeutic efficacy of osimertinib
Sites
1 site in 1 country
- Cancer Hospital ChineseBeijing, China